Ozeroff Christopher David's Form 4 filing
Oruka Therapeutics, Inc. (ORKA) · filed Nov 23, 2021
- Accession no.
- 0001209191-21-066497
- Filed
- Nov 23, 2021
- Trade date
- Nov 22, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $113.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ozeroff Christopher DavidCIK 0001454996 | Officer (S.V.P., General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 22, 2021 | Common Stock | PPurchaseAcquired | +50,000 | $2.26F1 | +$113,000 | 50,970 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $2.21 to $2.329. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.